Trial · NCT07898592
Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
NCT07898592, Not applicable, Not yet recruiting, Boston University Charles River Campus
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance. Trials, record NCT07898592. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898592
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
- NCT number
- NCT07898592
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Boston University Charles River Campus
- Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), Intellectual Disability, Learning Disorder, Communication Disorders, Down Syndrome, Fragile X Syndrome, Motor Tic Disorders
- Interventions
- EMPOWER-ND
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability of program content | baseline, 2-weeks, 4-weeks, 8-weeks | This outcome will be assessed by responses on the Program Feedback Scale (PFS), a 7-item self-report questionnaire to measure youth and participant acceptability, feasibility, and satisfaction with digital single-session interventions (SSIs). Response format is a 5-point Likert scale (Strongly Disagree (1) to Strongly Agree (5)). Total scores range from 7 to 35, with higher scores associated with greater program acceptability. |
| Primary | Utility of the program | baseline, 2-weeks, 4-weeks, 8-weeks | Utility will be assessed by the Family Accommodation Scale - Anxiety (FASA) questionnaire. FASA is a 9-item measure of how often family members change their own behavior to help a child avoid or ease anxiety. Each item is rated from 0 (never) to 4 (daily). Total score ranges from 0 to 36, with higher scores meaning more accommodation. |
| Primary | Child avoidance behaviors | baseline, 2-weeks, 4-weeks, 8-weeks | Child Avoidance Measure-Parent Report (CAMP), an 8-item questionnaire about how often the child avoids situations that make them anxious, scared, or worried. Each item is rated from 0 (almost never) to 3 (almost always), and items are summed for a total score from 0 to 24. Higher scores reflect greater avoidance. |
| Primary | Feasibility of the program | baseline, 2-weeks, 4-weeks, 8-weeks | Completion rates will be used to assess feasibility. |
| Secondary | Assessment of anxiety and related disorders | baseline 2-weeks, 4-weeks, 8-weeks | Anxiety and Related Disorders Interview Schedule (ADIS), a semi-structured clinical interview used to evaluate, diagnose, and measure the mood, obsessive-compulsive, trauma, and related disorders, will be administered to assess this outcome. It uses a Clinician Severity Rating (CSR) scale from 0 (none) to 8 (very severe), where scores of 4 or higher generally indicate a clinical diagnosis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898592
GET https://conductscience.org/api/trials/v1/NCT07898592/registered